Measurement of XXXX size from plasma @entity844 -binding protein or @entity5632 , using individually estimated clearance rates.

@entity1 @entity844 @entity8 @entity296 @entity908 @entity27216 @entity177 @entity1188 @entity1011 @entity5632 @entity583
OBJECTIVE: In @entity1 with @entity583 ( @entity583 ), estimation of @entity1188 size from the early markers, @entity844 -binding protein (FABP) and @entity5632 (MYO), usually assumes average (fixed) rate constants (FCR) for protein clearance from plasma. However, individual variation in FCR is large. @entity8 causes slower clearance of FABP and MYO from plasma and, hence, overestimation of @entity1188 size in 20-25% of @entity1 . We investigated whether or not more accurate values of @entity1188 size could be obtained with individually estimated clearance rates. METHODS: Concentrations of FABP and MYO and, for comparison, activities of the established cardiac markers, @entity908 kinase (CK) and @entity27216 dehydrogenase (HBDH), were assayed in serial plasma samples from 138 @entity1 with @entity583 . Individual FCR values of FABP and MYO were estimated from plasma @entity1011 concentrations, sex and age. RESULTS: Individual FCR values varied from 0.4 to 2.4 h-1. Use of these individual FCR values significantly improved the correlation between @entity1188 size, as estimated from FABP or MYO on the one hand, and from CK and HBDH on the other. Approximately equal estimates of @entity1188 size were obtained for all four marker proteins. CONCLUSIONS: Using individually estimated clearance rates, @entity177 no longer hampers calculation of @entity1188 size from FABP and MYO, and reliable estimates of total @entity296 can be obtained within 24 h after first symptoms.
